Follow the Elicio Therapeutics, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €83.8m. The latest transaction was filed on 3 February 2026 (Attribution). Among the most active insiders: DeMuth Peter. The full history is free.
9
Insider Decl.
n/a
Thresholds
€6m
1 ops.
Buy Volume
n/a
n/a
Sell Volume
19Σ signal
Buys €6mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,213,000 shares@ US$5.8125.1% of flowCommon StockSEC:0001209191-23-059683:0
Canonical exit: 21 Mar 2024 (T+90)
9 of 9 declarations
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a biopharmaceutical company focused on developing immunotherapeutic treatments for cancer. The company utilizes innovative technology to enhance patients' immune responses.